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P-glycoprotein (P-gp) and Multidrug Resistance Protein (MRP1) 
are the key cellular drug efflux transporters in a range of tissues 
and the radiopharmaceutical 99mTc-sestamibi has been 
demonstrated to be a substrate for both transporters in a number 
of in vivo and in vitro studies.  The elimination rate of 99mTc-
sestamibi from the lungs following inhalation as an aerosol has 
been shown to be delayed in healthy smokers versus non-
smokers. It was hypothesized that this was the result of smoke-
induced up-regulation of P-gp.  
The aims of this study were:  
To examine the relationship between the lung elimination rate of 
inhaled sestamibi and immuno-histochemical expression of 
broncho-pulmonary MRP1 and P-gp.  To study the repeatability of 
the technique and assess the effect of various demographic 
factors affecting the clearance of inhaled sestamibi. 
Methods:  
Thirty-five participants were included in the study. They all 
underwent an inhaled 99mTc-sestamibi clearance study. Of these, 
13 were patients undergoing surgery for primary lung cancer (5/13) 
or spontaneous pneumothorax (8/13). There were 22 healthy 
volunteers. All participants gave informed consent prior to the 
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study. Semi-quantitative assessment (grade 0-3) of MRP1 and P-
gp expression in lung on immuno-histochemical examination was 
correlated with the elimination rate of sestamibi from the lung 
tissue.  
The effect of various factors on inhaled sestamibi clearance 
including smoking status, age, gender and locality of residence 
was evaluated. The study was repeated in 10 participants to 
assess the repeatability and inter-observer reproducibility of the 
technique. 
Results:  
MRP1 expression was seen in 12/13 patients while P-gp in only 
2/13. The mean sestamibi elimination rate was faster in patients 
expressing low levels of MRP1 expression (grade 0-1), mean T½ 
of 105 ± 20 min, compared with those with higher levels of MRP1 
expression (grade 2-3), mean T½ of 149 ± 28 min (P = 0.008).  
Inhaled sestamibi clearance was significantly delayed in smokers 
(n=17), mean T½ = 142 ± 29 min, compared to non smokers 
(n=18), mean T½ = 91 ± 14 min (P < 0.0001). The clearance of 
inhaled sestamibi was also significantly delayed in non smoking 
older patients >30 y (n= 6), mean T½ = 101 ± 15 min, compared to 
younger patients <30 y (n=12), mean T½ = 86 ± 11 min (P < 0.05), 
and in non smoking men (n=7), T½ = 130 ± 37 min, compared to 
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women (n=11), T½ = 105 ± 28 min (P < 0.05).  
There was however no significant difference noted between urban 
dwellers from London (n=22), mean T½ = 89 ± 11 min, compared 
to semi-rural dwellers (n=13), mean T½ = 96 ± 20 min (P > 0.05). 
Bland-Altman analysis revealed excellent agreement between test 
and re-test values with a (bias) of 4.8 min and a standard deviation 
of the difference (precision) of 5.7 min. There was an excellent 
inter-observer reproducibility seen with a Spearman Rho value of 
0.96 and p<0.05 
Conclusion:  
The study results indicate a significant correlation between the 
predominant transporter in lung (broncho-alveolar epithelium) 
MRP1 and inhaled 99mTc- Sestamibi clearance. Inhaled 99mTc- 
Sestamibi clearance is a safe and reproducible technique. 
Smoking, increasing age and male gender appear to significantly 
prolong the lung clearance of inhaled sestamibi. There was 
however no definite effect of environmental status on the 







Chemotherapy in lung cancer was first studied in the late 1960s 
and since then has been used extensively in this disease (1,2). 
The use of chemotherapy has resulted in a fivefold increase in 
median survival and a long-term disease-free survival of over 3 
years in 5% to 10% of small cell lung cancer (SCLC) patients and 
4-15% improvement in median 5 year survival in non small cell 
lung cancer (3). 
Despite advances in cancer treatment, multidrug resistance (MDR) 
remains a major clinical problem resulting in poor patient outcome 
due to limited therapeutic options. This remains a major issue in a 
number of cancers, including leukaemia and carcinomas of the 
prostate, breast, lung and ovary. Significant efforts to gain a better 
understanding of the mechanisms that result in the development of 
drug resistance have been undertaken in order to improve the 
outcomes for current chemotherapy regimens in cancer treatment. 
MDR can develop in response to a specific drug or drug 
combination, due to phenotypes that typically confer resistance to 
a variety of agents.  
The mechanisms of resistance development are often diverse, 
including (a) insufficient uptake of water-soluble drugs by specific 
transporters, (b) alterations in cellular pathways which result in a 
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reduced capacity of cytotoxic drugs to kill cells, or (c) increased 
drug efflux from cancer cells. 
One of the important mechanisms of development of drug 
resistance has most often been linked to the over expression of 
Permeability glycoprotein (P-gp), a 170-kD ATP dependent 
membrane transporter that acts as a drug efflux pump. (4,5)  
 
3. Multidrug Resistance and the ABC transporters 
P-gp (permeability glycoprotein) 
The term “multidrug resistance” (MDR) describes the phenomenon 
where tumor cells develop a broad cross-resistance to a variety of 
structurally and functionally different cytotoxic drugs (6). It was first 
described in certain tumor cells that are protected against 
anticancer agents as a result of P-glycoprotein over expression 
(7). 
 
Preclinical studies have shown that resistance of tumour cells to 
cytostatic drugs derived from naturally occurring toxins is often 
closely related to the presence of a unique 170 kDa glycoprotein, 
called P-glycoprotein (P-gp) which is located on or in the cell 
membrane of the tumor cells. (7-9). This molecule acts by 
expelling these cytostatic drugs from the cytoplasm, causing drug 
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resistance, at least in vitro (10-13). Studies have demonstrated 
expression P-gp in normal human tissue including the lungs. (14-
16). P-gp expression has also been demonstrated on (and in) cells 
with secretory and excretory functions (proximal tubules, bile 
canaliculi, glands in the prostate and breast, sweat glands, 
intestinal epithelia), which suggests a physiological role in removal 
of potentially toxic substances (17-19).  
A significant understanding of the functional role of P-glycoprotein 
in drug transport was described by Schinkel et al using P-
glycoprotein-deficient mice (20, 21). They elegantly demonstrated 
the result of inhibition of the mouse P-glycoprotein gene leads to a 
deficiency in the blood-brain barrier and increased sensitivity to 
drugs. Also, they compared the drug concentrations in various 
tissues in P-glycoprotein-expressing and P-glycoprotein-deficient 
animals and demonstrated the cell protective value of this 







P-gp Structure and interaction: 
P-gp, encoded by the human MDR1 gene located on chromosome 
7, is one of 48 known human ATP binding cassette (ABC) 
transporters. It is a 170 kDa molecular weight phosphoglycoprotein 
consisting of 1280 amino acids and consisting of two ATP binding 
cassettes and two transmembrane regions. (23). The N-terminal 
half of the molecule contains 6 transmembrane domains, followed 
by a large cytoplasmic domain with an ATP-binding site, and then 
a second section with 6-transmembrane domains and an ATP-
binding site that shows over 65% of amino acid similarity with the 
first half of the polypeptide (24). 
 
P-gp can recognise and bind a large variety of hydrophobic 
natural-product drugs as they enter the plasma membrane. These 
include many of the commonly used anticancer drugs, such as 
doxorubicin and daunorubicin, vinblastine and vincristine, and 
taxol, as well as many commonly used pharmaceuticals ranging 
from antiarrhythmics and antihistamines to cholesterol-lowering 
statins (25) and HIV protease inhibitors (26). Binding of these 
drugs results in activation of one of the ATP-binding domains, and 
the hydrolysis of ATP causes a major change in the shape of P-gp, 
which results in release of the drug into the extracellular space 
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(27). Hydrolysis of a second molecule of ATP is needed to restore 
the transporter to its original state so that it can repeat the cycle of 
drug binding and release (28, 29). Although the detailed 
mechanism of action of other ABC transporters is not known, it is 
presumed that the ATP binding cassette acts as the engine for the 
transport mediated by members of this large family of transporters. 
 
The discovery of P-gp and the demonstration of its widespread 
expression in many human cancers was a significant step towards 
understanding the development of drug resistance. However, it 
was found that many multidrug-resistant cancers, such as lung 
cancers, rarely express P-gp (30-33). P-g-p expression was at 
best heterogeneous, ranging from rare scattered cells to a positive 
pattern for nearly all cells considered, without any relationship with 
pathologic and clinical prognostic variables (31). 
As a result, a search for other efflux pumps that may be 







Multidrug resistance associated protein 1 - MRP1 
Using a multidrug-resistant lung cancer cell line as a model 
system, Deeley, Cole and colleagues (34) cloned another ABC 
family member, known as MRP1 (multidrug resistance associated 
protein 1), a 190 kDa molecular weight protein. It was originally 
identified as being responsible for MDR in a doxorubicin-selected 
human small cell lung carcinoma cell line. Even though these cells 
displayed an MDR phenotype similar to that previously associated 
with P-gp over expression, resistance was found to be P-gp-
independent (34, 38). MRP1 is also widely expressed in many 
human tissues and cancers (35). 
 
MRP1 has since been closely linked to the development of clinical 
MDR in several types of cancer (36, 37), and an extraordinarily 
wide variety of transport substrates have been identified, showing 
that it has a broad spectrum of anticancer drug transport activity 
(34).  
 
MRP1 structure and interaction 
MRP1, unlike MDR1 proteins, transports negatively charged 
natural products and drugs that have been modified by glutathione 
(GSH), conjugation, glycosylation, sulfation, and glucuronylation. 
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In some cases co-transport of glutathione with positively charged 
drugs, such as vinblastine, can occur. MRP1 also transports 
diverse physiological substrates such as folates, GSH and GSH 
disulfide (GSSG), as well as sulphate-, GSH- and glucuronide-
conjugates of steroids, leukotrienes and prostaglandins (37, 39). 
The activities of MRP1 are important in normal cellular processes, 
such as export of endogenous intermediates and protection from 
toxic insult. MRP1 over expression in cancer cells allows the 
elimination of a wide range of therapeutic agents, and due to its 
ability to influence cellular GSH-GSSG balance through export of 
GSH and its derivatives, MRP1, could play an important role in the 
cellular response to oxidative stress induced by drugs or 
associated with various disease states. 
Up-regulation of MRP1 has been observed in a variety of solid 
tumours such as those of the lung, breast and prostate, and this 
transporter has been clearly implicated as having a role in the 
clinical drug resistance behaviour of several of these cancers. 
The most common type of lung cancer, non-small cell lung 
carcinoma (NSCLC), is typically chemoresistant and MRP1 was 
found to be over expressed in a large proportion of these cancers 
prior to treatment exposure. MRP1 expression correlated strongly 
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with poor response to chemotherapy and poor overall survival (38). 
MRP1 expression was also predictive of poor response to 
chemotherapy in small cell lung carcinoma (SCLC) (38).  
MRP1 and P-gp expression were noted to be increased in SCLC 
metastases detected at relapse, suggesting a role for these 
transporters in cell survival during metastasis and chemotherapy 
(40). 
 
Prime drug efflux transporter in lungs; P-gp Vs MRP1 
While studies have revealed high levels of P-gp expression in most 
tumours derived from tissues expressing P-gp, a discrepancy was 
sometimes found between the level expressed in the tumour and 
adjacent normal tissues, particularly within the lungs (13-15). 
Wright et al and Berger et al (41, 42) interestingly observed strong 
expression of MRP1 in normal broncho-alveolar epithelium with a 
distinctly increased expression in tumour cells (adenocarcinomas, 
carcinoid tumours and SCLC tumours) as compared with the 
normal cell counterpart. They however observed a very weak or 
negative expression of P-gp and limited expression of lung 
resistance protein (LRP) both in the normal lung tissue and 
chemotherapy-naïve tumour tissue. Berger et al (42) observed that 
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P-gp expression in lung tumours was only increased in those 
patients who had been exposed to chemotherapy prior to surgery. 
 
Despite the positive results of a small, randomized study of the 
addition of verapamil (as a P-gp inhibitor) to chemotherapy in 
untreated NSCLC (40), three large randomized trials failed to show 
any benefit of agents that reverse the MDR phenotype in terms of 
the response to chemotherapy or the length of survival. One of 
these trials was performed in untreated patients with SCLC and 
failed to demonstrate any benefit of adding verapamil to 
chemotherapy (43). 
 
Narasaki et al. investigated the expression of MRP mRNA and 
drug sensitivity in lung cancer cell lines and tested the modulating 
effects of verapamil. They demonstrated clear correlations 
between the MRP gene level and the sensitivity to etoposide and 
doxorubicin usage. They also demonstrated various levels of MRP 
gene expression but not the MDR1 gene in the cell lines and also 




MRP1 appears to be expressed at a basal level in normal lung 
tissue and it is therefore important to measure MRP1 expression in 
normal cells as a baseline and compare to that in malignant cells 
(45). 
 
Other ABC transporters 
Other ABC transporters have also been implicated in the 
development of drug resistance and are of potential significance, 
including the MDR2 gene product (46, 47), a protein named SPGP 
(sister of P-gp) (48), and ABC A2 (49). Other members of the ABC 
transporter family in addition to the MDR, MRP, and MXR family 
members  have also been implicated in clinical cancer drug 
resistance or in drug transport in humans and efforts to explore 







4. 99mTc-Sestamibi (methoxyisobutyl isonitrile) for 
demonstrating P-gp /  MRP1 function 
The technetium-99m-labeled complexes, sestamibi ([99mTc]-MIBI) 
and tetrofosmin ([99mTc]-TFS), originally designed for myocardial 
perfusion studies, are recognized by P-gp and MRP1 as transport 
substrates.(50–53). These agents are cationic and modestly 
hydrophobic, thus sharing common characteristics of cytotoxics 
comprising the MDR phenotype. (54, 55)  
Many in vitro and in vivo studies have demonstrated correlation 
between the uptake and/or retention of these radiotracers and the 
expression levels of P-gp or MRP1 in tumour cells (50, 52, 56–61). 
Therefore, [99mTc]-MIBI and [99mTc]-TFS have been proposed as 
imaging probes for MDR assessment and to monitor the efficacy of 
MDR modulators. They have also been used as imaging agents in 






5. Effect of smoking on P-gp and MRP expression and 
functionality 
Little is known about the factors affecting functionality of P-gp or 
MRP1 in the lungs. Ex vivo data from human lung suggests that 
pulmonary P-gp is up-regulated by cigarette smoke (66, 67) and 
MRP1 is down-regulated in chronic obstructive pulmonary disease 
(COPD) (68). Van der deen et al demonstrated that exposure to 
cigarette smoke extract (CSE) up regulates MRP1 expression and 
also competitively inhibits MRP1 activity in the bronchial 
epithelium, resulting in increased CSE related cytotoxicity. It was 
therefore suggested that MRP1 had a possible protective role 
against COPD (69).  
Sam et al demonstrated in smokers, tobacco chewers and 
alcoholics, an increased polymorphism of the ABCB1 gene that 
encodes P-gp, which was associated with increased risk of aero-
digestive tract cancers (70). 
In Volm et al. study, 58% of lung cancers in smokers, compared 
with 9% in non-smokers, expressed P-gp (71). In the study by 
Lechapt-Zalcman et al (15), however, different levels of expression 
of P-gp in bronchial tissue had been observed between individuals 
in the two groups (smokers vs non smokers) evaluated, with a 
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higher mean in the smokers group, although with no statistically 
significant difference.  This raises the question as to whether 
smoking does result in increased P-gp expression or whether there 
is increased functionality of P-gp in these patients.  
 
6. Inhaled 99mTc-sestamibi clearance imaging in 
human lungs 
Recently, Ruparelia et al (72) described the technique of studying 
the clearance of inhaled aerosolised 99mTc-sestamibi from human 
lungs in healthy volunteers. This involved the participants inhaling 
aerosolised 99mTc-sestamibi via a ventilation kit during relaxed tidal 
breathing in the sitting position. Regions of interest were placed 
around the periphery of both lungs, excluding the central airways. 
Time–activity curves were generated for each lung, summed and 
corrected for the physical decay of 99mTc.  
They observed that the lung elimination rate of 99mTc-sestamibi 
following inhalation as an aerosol in normal non-smoking humans 
is much slower than would be expected from its molecular size and 
physical properties and about half as fast as that of the hydrophilic, 
radio-aerosol, technetium-99m-diethylenetriaminepentaacetic acid 
(99mTc-DTPA) (72). No activity was seen in the airways or GI tract 
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for several hours after 99mTc-sestamibi inhalation, confirming that 
elimination of radioactivity took place across the gas-blood barrier.  
Unlike inhaled 99mTc-DTPA, the lung elimination rate of which is 
markedly accelerated in cigarette smokers (73), 99mTc-sestamibi 
elimination rate was noted to be markedly delayed in smokers 
compared with non-smokers. Also in contrast to 99mTc-DTPA, 
99mTc-sestamibi elimination was not accelerated in interstitial lung 
disease. It was, however, significantly delayed in ex-smoking 
patients with chronic obstructive pulmonary disease (73).  
The lung elimination rate of the related compound, 99mTc-
tetrofosmin, was also slower than that of 99mTc-DTPA, but in 
contrast to 99mTc-sestamibi interestingly not delayed in cigarette 
smokers (74).     
While 99mTc-DTPA crosses the gas-blood barrier in the lungs by 
passive diffusion through inter-epithelial junction gaps, a lung 
elimination rate of inhaled 99mTc-sestamibi slower than that of 
99mTc-DTPA was therefore hypothesized to be due to intracellular 
99mTc-sestamibi binding in airway epithelium (74). It was also 
suggested that the elimination would be further delayed if lung P-
gp pumped the tracer back into the airways and that the slow 
elimination rate seen in smokers was the result of smoke-induced  
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upregulation of P-gp.  A similar smoke-induced delay of 99mTc-
terofosmin clearance was not seen because this compound is less 
P-gp avid (72).  
 
7. Current techniques of demonstrating P-gp 
expression in cells: 
To date the gold standard for demonstrating the presence of P-gp 
in cells has been histopathological demonstration of the presence 
of P-gp in the tissue specimen. Various techniques including 
immunohistochemical, immunocytochemical (14) and Western blot 
analysis have been performed on histological specimens to 
demonstrate the level of expression of P-gp in the cells. 
 
Several different monoclonal antibodies have been used for the 
immunohistochemcial quantification of P-gp expression, some of 
which bind extracellular epitopes and some intracellular epitopes.  
 
However, immunohistochemical assessment of tissue P-gp 
expression is not without its share of problems. Tissue P-gp 
expression is antibody- as well as tissue-dependent and described 
as heterogeneous throughout tissues (31). Immunoreactivity is not 
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specific which could result in false positive results (12). Other 
potential problems include sampling errors, tissue fixation effects 
(14) or failure of P-gp expression to translate to function.  
 
Apart from histological demonstration of P-gp in cells, intravenous 
injection of 99mTc-sestamibi is the current technique used to look at 
the expression of P-gp in vivo and predict chemotherapy 
resistance in patients. Although studies have shown this to be a 
reasonably accurate technique (75- 77), there is a significant 
overlap noted between responders and non-responders in these 
studies affecting the specificity of the technique. There are no 
prospective studies however performed to confirm the value of the 
technique. 
 
Whilst immunohistochemistry is regarded as the gold standard for 
P-gp expression, retention and elimination of a P-gp substrate 
represents an attractive alternative for the in vivo measurement of 





8. Aims and Rationale of the study 
The primary aim of this project was to explore the relation between 
broncho-pulmonary P-gp / MRP1 expression and the transfer of 
inhaled 99mTc-sestamibi from airspace to blood. The secondary 
aims were to determine the repeatability of inhaled 99mTc-sestamibi 
clearance technique and explore the effect of patient and 
demographic factors on the clearance of inhaled 99mTc-sestamibi. 
The primary aim was addressed firstly by correlating the inhaled 
99mTc-sestamibi elimination rate from the lungs with 
immunohistochemical expression of P-gp and MRP1 in surgically 
resected normal lung tissue. 
We would also look at the location of these transporters within the 
broncho alveolar epithelium on immunostaining which would 
support the hypothesis of these transporters playing a role in the 
clearance of inhaled 99mTc-sestamibi from the lungs. 
The repeatability of the technique was assessed in 10 patients 
who underwent a repeat study within 2-4 weeks of the primary 
study.  An inter-observer reproducibility was assessed in 5 
patients. The effect of patient factors including smoking status, 
age, gender and the possible effect of locality of patient residence 
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was correlated with inhaled 99mTc-sestamibi clearance in these 
patients.  
If the presumed hypotheses were proven, inhaled 99mTc-sestamibi 
clearance may prove to be a very useful technique to assess the 
functional expression of P-gp / MRP1 in patient lungs and obviate 
the necessity to obtain tissue samples by invasive biopsy. It would 
provide a simple, reproducible, economical outpatient procedure 
with minimal exposure to radiation (~0.5 mSv compared to 8 mSv 
for iv 99mTc-sestamibi study) providing crucial information regarding 
functional status of lung drug efflux transporters in patients. 
This crucial information may help tailor the treatment to the patient 
and may also help understand the role these transporters play in 









9. Study design, Materials & Methods 
Institutional Ethics committee approval was received for this 
prospective study. Informed written consent was obtained from all 
participants in the study. The study was conducted in compliance 
with the principles of the Declaration of Helsinki (1996), the 
principles of GCP and all of the applicable regulatory 
requirements. 
Patient characteristics 
35 participants were included in the study. 13 of these participants 
were patients who were planned to undergo lung surgery recruited 
from the thoracic surgical clinic dealing with the management of 
patients with lung cancer and spontaneous pneumothorax. 22 
were normal healthy volunteers recruited via the trial recruitment 
service at King’s College London. 
Inclusion criteria: 
We included patients aged 18 years or more. They were all able to 
provide informed consent and able to lie supine for 40 minutes 
under the gamma camera. 
Exclusion criteria: 
We excluded patients who were less than 18 years of age, 
pregnant patients or if they were taking known P-gp / MRP1 
modulating medication.  
 27 
Nineteen potential patients from the thoracic surgical clinic who 
were planned to undergo surgery for primary lung cancer or 
recurrent pneumothorax were screened. Thirteen patients 
undergoing surgery for primary lung cancer (5/13) or spontaneous 
pneumothorax (8/13) consented to the study. 
 A further 64 healthy volunteers were screened of whom 22 agreed 
to participate in the study. 
All the participants underwent an inhaled sestamibi clearance 
study. The clearance study was repeated in 10 participants to 
confirm the repeatability of the technique. 
 
Of the 35 participants, there were 17 who were smokers and 18 
non smokers. 17 were male and 18 female while13 participants 
resided in a semi rural location (West Sussex) and 22 resided at 
an urban (London) address. 
Age of the participants ranged between 20 -78 with a mean of 38 
years. Concomitant medication intake was recorded in all the 
participants. None of the participants were noted to be on P-gp or 




Inhaled 99mTc-sestamibi clearance study acquisition 
parameters 
400 MBq of 99mTc-sestamibi was placed in the Smart Vent 
nebuliser (Diagnostic Imaging Ltd). The nebulised radioactive 
tracer was inhaled for 1- 5 minutes by the participant, sitting 
upright, via a mouth piece until a count rate of at least >0.3 
Kcounts per second was recorded. This was in keeping with the 
departmental guideline (ventilation / perfusion scintigraphy) to 
ensure diagnostic quality images were obtained in all patients. 
Participants were instructed to lie supine on couch of the Siemens 
Symbia ™ dual head large field of view gamma camera. Anterior 
and posterior images of the chest were acquired dynamically at a 
rate of 2 seconds per frame starting immediately after inhalation 
was completed. Matrix size was 64 X 64 and no zoom applied. The 
imaging was carried on for 40 minutes. 
Images were transferred to Hermes (Hermes Medical, Stockholm) 
workstation for analysis. 
Radiopharmaceutical purity was tested on every batch used in the 
patients. All batches demonstrated radiochemical purity typically 
>97% as confirmed by daily quality control procedures. 
This was to ensure any impurities like colloids which could be 
taken up by the alveolar macrophages and potentially affect the 
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study were excluded. All the images were evaluated for the 
presence of free pertechnetate in the radiopharmaceutical by 
including the thyroid and the stomach in the field of view. None of 
the studies demonstrated contamination with free pertechnetate.   
 
Analysis of Inhaled 99mTc-sestamibi clearance 
 Analysis of the dynamic images was performed on Hermes work 
station using the default dynamic study analysis software package.  
Regions of interest were drawn around both lungs on the anterior 
and posterior images. Time activity curves were generated for both 
lungs and the effective half life (T½) for clearance of activity from 
the lungs over a period of time was calculated by fitting curves to 
first order equation. The individual lung clearances were obtained 
as geometric mean of the anterior and posterior clearance results.  
In 10 participants the inhaled 99mTc-sestamibi clearance study was 
repeated within 2-4 weeks of the initial study, to assess the 
repeatability of the technique. In 5 participants the inhaled 
sestamibi clearance was assessed by a second experienced 
nuclear medicine clinician. The individual clearance for each lung 
was compared between the two readers to assess the inter-
observer reproducibility.  
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A first order exponential curve fitting was used to assess the 
elimination rate as we also wanted to assess the effect of varying 
breathing techniques in different participants.  
  
Tissue Immunohistochemistry: 
Paraffin embedded lung tissue obtained from the participants who 
underwent surgery for underlying disease was subjected to 
immunohistochemical examination for the presence of P-gp and 
MRP1. Immunohistochemistry was performed using the Ventana  
BenchMark ULTRA staining machine (Ventana Medical Systems 
Inc, Tucson, AZ, USA). Immunostaining procedure was 
standardised using human Gut epithelium as control tissue. 
(Figures 1a and 1b) JSB-1 mouse antibody (AbCam ab 3366, 
AbCam, Cambridge, UK)) was used for P-gp detection (1/50) and 
Anti-MRP-1 mouse antibody MRPm5 (AbCam ab 24102, AbCam, 
Cambridge, UK) was used for MRP-1 detection (1/100). 
Antigen retrieval was performed following incubation of in Ultra 
CC1 (Tris/Borate/EDTA buffer pH 8-8.5), for 36 min, at 95°C. 
Antibody was diluted in Antibody Diluent (Dako Real S2022, 
DAKO, Denmark). 
Primary Antibody was incubated at 36°C for 32 min and secondary 
antibody was incubated at 36°C for 30 min. 
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Tissue was counterstained with hematoxylin II for 4 min followed 
by Bluing Reagent for a further 4 min. Following this, slides were 
washed in soapy water, dehydrated through serial alcohol dilutions 
- 70% and 100% twice for 2-3 min each and twice with Xylene for 3 
min each. The slides were mounted in Eukitt (Sigma 03989, 
Sigma-Aldrich, Dorset, England) for analysis. 
A semi quantitative method for evaluating P-gp and MRP-1 
expression was based on the strength of immunostaining, which 
was graded into 4 categories;  
Negative = 0, weak =1, moderate = 2 and strong = 3. (fig 1c) 
The immunohistochemical analysis of P-gp and MRP1 expression 
in the normal lung tissue surrounding the cancer / bullous lung 
tissue and within the cancerous lung was performed by an 









10. Statistical analysis 
Statistical advice was sought from a statistics expert. 
The study was powered to demonstrate a difference of 20% or 
more in the mean inhaled sestamibi clearance between patients 
expressing negative / weak drug transporter status (Grades 0-1) 
compared to moderate / strong drug transporter status (Grades 2-
3) as assessed by immunohistochemistry and a minimum of 13 
patients was advised. 
Repeatability of the Inhaled 99mTc-sestamibi clearance technique 
was assessed using Bland-Altman analysis to test agreement 
between the test and retest values. A Spearman Rho calculator 
was used to test the inter-observer reproducibility of the technique. 
Clearance time for 50% of inhaled 99mTc-sestamibi from the lungs 
(T½) was compared between different groups of patients to study 
the effect of: smoking, gender, age and the quality of inhaled air as 
assessed by the dwelling status of the patient, urban or rural (as 
an expected surrogate). 
Mean inhaled sestamibi clearance values and the standard 
deviation were calculated. 
Parametric testing using Student’s t-test (2 tailed) and non-
parametric testing using Mann-Whitney test and Spearman’s Rho 
test were applied to the data.  
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11. Results 
The individual lung clearances were obtained and compared with 
each other. A Spearman Rho test was used to check the 
correlation between the right and left lung clearances (Table 1). 
This confirmed an excellent correlation between the individual lung 
clearances, p<0.05 with an R value of 0.95. We obtained the mean 
of the two lung clearance values as a single inhaled 99mTc-
sestamibi clearance for each patient.  
a) Immunohistochemistry and inhaled  99mTc-sestamibi 
clearance results (n=13) 4 non-smokers and 9 smokers  
Expression of P-gp was negative, grading 0, in 11 / 13 (Fig 2a) and 
only weakly positive, grading 1, in 2/13 patients. 
  
MRP1 expression was demonstrated in 12/13 patients (Fig 2b) 
with negative MRP1 expression noted in only 1 patient within the 
healthy broncho-alveolar epithelium.  
The MRP1 staining was noted to be located predominantly in the 
apical aspect of the broncho-alveolar lining epithelium with some 
staining also seen at the basolateral aspect. (Fig 2c) 
 
Clearance of inhaled 99mTc-sestamibi was significantly delayed in 
patients demonstrating upregulated MRP1 levels, grading ≥2, n=7 
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(T½= 148.8 ± 27.8 min) compared to those expressing low MRP1 
levels, grading ≤1, n=6 (T½= 104.8 ± 20.1min) p=0.008 (Fig 3a 
and 3b). 
 
Non-smokers (n=4) demonstrated low levels of MRP1 expression 
0 (n=1) and 1 (n=3) while MRP1 levels were up regulated in 9 
smokers, 1(n=1), 2 (n=5) and 3 (n=3).  
In contrast, there was no difference in the P-gp expression 
between smokers and non-smokers. 
 
In all 5 patients with lung cancer, MRP1 levels were upregulated in 
the cancer tissue (grade 2-3) compared to the normal epithelium 
(grade 1-2). 
 
b) Reproducibility (Fig 4a and 4b) 
Ten participants underwent repeat inhaled 99mTc-sestamibi 
clearance study within 4 weeks of the initial study.  
Bland-Altman analysis of the data revealed that in 9 / 10 (Fig 4a) 
participants the difference between the test and retest values was 
within two standard deviations with a (bias) of 4.8 min and a 
standard deviation of the difference (precision) of 5.7 min 
suggesting excellent agreement. In one patient in whom the 
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difference was >2SD it was noted that the participant who was a 
smoker, had stopped smoking at least 2 weeks prior to the second 
test which may explain the significant difference between the two 
results. The results including the 10th patient are presented in Fig 
4b with a (bias) of 7.1 min and a standard deviation of the 
difference (precision) of 9.3 min. 
There was an excellent inter-observer reproducibility seen with a 
Spearman Rho value of 0.96 and p<0.05 (Table 2a) for the 
individual lung clearances. The Spearman Rho was 0.99 and 
p<0.001 (Table 2b) between the 2 reviewers for the clearance 
values measured as a mean of both lung clearance values for 
each patient. 
 
c) Smokers (n =17) vs Non Smokers (n = 18) (Fig 5) 
Mean inhaled MIBI clearance T½ for smokers was 142.2 ± 29.3 
min and that for non-smokers was 90.5 ± 14.1 min demonstrating 
a significant (p < 0.05) delay in inhaled 99mTc-sestamibi clearance 
in smokers. 
As smoking seemed to have a significant impact on the inhaled 
sestamibi clearance, we studied the effect of gender, age and 
environmental status in non-smokers separately to eliminate any 
confounding bias. 
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d) Gender - Male (n = 7) vs Female n = 11) non smokers (Fig 6) 
The calculated mean T1/2 values for males was 130.3 ± 37.0 min 
which was delayed when compared to female participants with a 
mean T1/2 value of 105.6 ± 27.9 min (p = 0.037). 
In the smokers, there was no significant difference (p=0.211) seen 
between the male participants (n=10) 151.3 ± 28.9 min and 
females (n=7), 129.6 ± 29.1 min. 
 
e) Rural Vs Urban (n = 13 vs 22) (Non smokers London n = 12 
vs semi rural n = 6) (Fig 7) 
There was no significant difference in the mean T1/2 times 
between non-smoking participants living in an urban area (London; 
89.0 ± 11.02 min (n = 12) compared to participants living in a semi 
rural area (West Sussex; 95.8 min ± 20.0 min. p = 0. 36)  
In the smokers, there was no significant difference (p=0.87) seen 
between the London participants (n=7) 140.8 ± 35.3 min and west 
sussex participants (n=10), 143.3 ± 26.3 min. 
 
 
f) Age (Non smokers <30 years n = 12 vs >30 n = 6) (Fig 8) 
There was a trend of increased inhaled 99mTc-sestamibi clearance 
times with age. There was faster clearance seen in those <30 
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years, n= 12, exhibiting a mean clearance of 86.0 ± 11 min 
compared to those >30, n=6 a mean clearance of 100.6 ± 14.5 min 
(p = 0.027). 
In the smokers, there was no significant difference (p=0.97) seen 
between the participants <30 years 142 ± 24.6 min (n=8) and 
those >30 years age (n=9), 142.4± 34.5 min. 
 
12. Discussion: 
The prominent expression of P-gp and MRP1 in the human lung 
(78) suggests that these transporters may play an important role in 
the protection against endogenous or exogenous toxic compounds 
entering the lung. The delivery of pulmonary drugs to reach their 
site of action may also be affected by the presence and activity of 
these drug transporters (79).  
 
It is known that in drug-resistant cells both P-gp and MRP1 may be 
over expressed at the same time (80, 81). 
However there remains a debate about the role of P-gp as a major 
drug transporter in human lungs.  
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Inhaled 99mTc Sestamibi clearance and drug transporter 
expression in lungs 
 
In the present study very little or no P-gp expression was identified 
in the broncho-alveolar epithelium while there was clear MRP1 
expression noted on immunohistochemical analysis of normal lung 
tissue and lung tumours. Furthermore, we demonstrate a 
significant delay in the clearance of inhaled sestamibi, an 
established MRP1 substrate, from the lungs in patients with higher 
MRP1 expression (Grade 2 & 3) compared to those with low or no 
MRP1 expression (Grade 0 & 1) (Fig 4a and 4b). 
 
The expression of P-gp within the broncho-alveolar epithelium and 
its role in facilitating transfer of the substrates has been 
researched previously.  The current opinion is that P-gp is mainly 
expressed in the larger tracheo-bronchial airway epithelium while 
there is no significant expression in broncho-alveolar epithelium 
(82). 
 
Wright et al and Berger et al, in their studies (41,42), interestingly 
observed strong expression of MRP1 in normal broncho-alveolar 
epithelium with a distinctly increased expression in tumour cells as 
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compared with the normal cell counterpart, while they observed 
very weak or negative expression of P-gp and limited expression 
of lung resistance protein (LRP) both in the normal lung tissue and 
chemotherapy naïve tumour tissue. Berger et al (42) also observed 
that P-gp was expressed significantly higher (p <0.05) in tumor 
tissues for patients who had undergone neo-adjuvant 
chemotherapy before surgery.  
 
Hendrikse et al (83) demonstrated functional modulation of these 
proteins with specific blockers while Schinkel et al (84) observed in 
the lung tissue of the P-gp knockout (-/-) mice that the level of 3H-
digoxin (P-gp substrate) was low compared to other organs 
suggesting a limited role for P-gp as a drug transporter in the 
lungs. In keeping with the literature evidence the current study did 
not identify significant P-gp expression in the chemotherapy naïve 
lung tissue.  
 
To support the transporter effects of these proteins, their 
localisation is a key factor. The likely location of MRP1 and other 
ABC transporters within the broncho alveolar epithelium has been 
described variably in the literature. This has been well summarised 
and best explained by van der deen et al (82) in their study.  
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In this study we were able to clearly demonstrate the cytoplasmic 
presence of MRP1 and its preferential apical expression in the 
bronchoalveolar epithelium (fig 2c). This is a finding which has not 
been well documented in the literature previously. 
The expression of MRP1 was observed in basolateral aspect of 
the ciliated epithelial cells (Fig 2c). 
 
We speculate that while the transfer of the inhaled 99mTc-sestamibi 
is driven by the difference in the action potential across the cell 
membrane, once it is inside the cell (cytoplasm) the apical MRP1 
expression likely mediates its transfer across the membrane back 
into the airspace.  The basolateral expression of the MRP1 within 
the cells we feel would likely facilitate the transfer of the 
intracellular 99mTc-sestamibi into the capillaries (circulation) as 
noted by the appearance of the tracer in the systemic circulation 
during the later part of the study (fig 9).  
 
Decreased or increased functional MRP1 expression may have an 
impact on development and/or progression of lung diseases and 
protection against air pollution and inhaled toxic substances. 
Indeed, Van der deen et al observed lower MRP1 expression in 
patients with chronic airway disease and postulated that the lower 
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expression of MRP1 or the down-regulation of MRP1 may result in 
an increased vulnerability to, and subsequent development of, 
chronic airway disease (68). 
 
Imaging the kinetics of known drug transporter substrates across 
the alveolo-capillary membrane using inhaled clearance technique 
provides a very interesting model to directly interrogate the effects 
of drug transporters on a large variety of inhaled pulmonary 
therapeutic agents, such as corticosteroids and sympathomimetics 
that may be substrates for these transporters in the lung or 
modulate their activity. Functional inhalation studies would also 
provide an excellent opportunity to demonstrate effects of inhaled 
toxic substances, as postulated by van der deen et al (68). 
 
Inhaled 99mTc-sestamibi clearance is a functional imaging 
technique that was first described by Ruparelia et al in 2008 (72). 
They studied the clearance of inhaled sestamibi in normal human 
volunteers and patients with chronic obstructive pulmonary 
disease (COPD). They observed significant differences in inhaled 
sestamibi clearance rates between smokers and non-smokers 
while no significant difference was seen between healthy 
volunteers compared to COPD patients. They postulated that the 
 42 
delayed clearance of sestamibi across the alveolo-capillary barrier 
was regulated by active binding and efflux of sestamibi by P-gp 
expressed in the lung tissue (72). They also postulated that 
delayed sestamibi clearance in smokers compared to non-smokers 
was due to active efflux of inhaled sestamibi mediated by 
increased P-gp expression in the alveolar epithelium, pumping it 
back into the airspaces (74). Interestingly, this group showed no 
difference between smokers and non-smokers with respect to the 
lung clearance rate of inhaled tetrofosmin (74). There was 
however no immuno-histochemical correlation available to confirm 
the postulation.  
The findings of van der deen (68) and Ruparelia (72) are 
interesting particularly in the COPD population. While van der 
deen et al observed low MRP1 expression in COPD subjects, 
Ruparelia et al demonstrated faster clearance of inhaled sestamibi 
in these subjects in their study.  
The initial response to cigarette smoke exposure is one of 
increased MRP1 expression as a protective effect. However with 
prolonged heavy smoking, there is a competitive inhibition of the 
MRP1 thereby leading to loss of protective effect and development 
of COPD which would explain the findings of both van der deen et 
al and Ruparelia et al. 
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While immunohistochemistry is regarded as the gold standard for 
determination of MRP1 expression in lung epithelium, the 
technique is limited by heterogeneous expression of drug 
transporters in the lung tissue. The demonstration of expression is 
dependent on antibody selection and also remains tissue-
dependent (31). Immunoreactivity is not specific which could result 
in false positive results (11). Other potential problems include 
sampling errors, tissue fixation effects (14) and failure of protein 
expression to translate to function.  
 
In contrast, functional imaging using radiolabelled drug transporter 
substrates represents an attractive alternative approach for the in 
vivo measurement of functional expression and moreover is 
independent of histological sampling errors.  
 
On review of the literature, functional imaging studies 
demonstrating the role of MRP1 in lungs remains very limited.  
Apart from a single animal study by Okamura et al (85) who 
demonstrated MRP1 as the prime drug transporter across the lung 
epithelium with P-gp playing no significant role, there is a lack of 
 44 
functional imaging studies demonstrating the role of MRP1 in 
lungs.  
 
Our study is the first in vivo study to our knowledge that 
demonstrates a significant correlation between the functional 
inhaled 99mTc- sestamibi clearance technique and the 
immunohistochemical expression of MRP1 in human lungs. We 
were able to demonstrate the localisation of the MRP1 within the 
broncho-alveolar epithelium which would support the hypothesis 
that the increased expression of the transporter protein (MRP1) in 
these cells, likely regulates the clearance of inhaled sestamibi.  
 
Interestingly we observed while there was expression of MRP1 in 
the normal broncho-alveolar epithelium, it was consistently 
upregulated in the lung tumour tissue as seen on 
immunohistochemistry although the number of patients with lung 
cancer was small, n=5. This is similar to the observations of Wright 
et al and Berger et al (41, 42). However it is difficult to know 
whether the increase in MRP1 expression noted in the normal lung 
tissue was already increased prior to the onset of cancer or is a 
result of the systemic effect of the cancer. 
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It is likely that the increased MRP1 expression in the cancer tissue 
is a combination of factors affecting the MRP1 expression and the 
inherent protective effect developed by the cancer cell to escape 
the immune system response. 
 
Factors affecting MRP1 expression and inhaled sestamibi 
clearance 
There are very few studies assessing the factors affecting MRP1 
expression in lungs while inhaled 99mTc-Sestamibi clearance is a 
novel technique.   
 
Cigarette smoking appears to be one of the main factors affecting 
MRP1 expression in human lungs. Van der deen et al (67) 
observed that exposure to cigarette smoke upregulated MRP1 
levels in humans. However, MRP1 expression, as assessed by 
immunostaining, was lower in bronchial biopsies of COPD patients 
as compared to that in healthy patients as well as in patients 
affected by severe COPD versus those with a mild to moderate 
form of the disease. (66) Consequently, they postulated that (69) 
following exposure to cigarette smoke there is upregulation of 
MRP1 expression in lungs as a protective mechanism. However 
with sustained and significant smoking exposure resulted in 
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competitive inhibition of the protective MRP1 up regulation and 
thereby resulting in cigarette smoke induced damage to the 
alveolar epithelium.  
However in a different study, MRP1 mRNA levels were not 
statistically different in healthy smokers, ex-smokers and non 
smokers in a study by Breechot et al. (80)  
 
These are important observations as they highlight the importance 
of the limited understanding we have regarding these transporters 
and their functional significance in the development of pathology 
and its progression.  
 
 
Wright et al (41) and Berger et al (42) looked at the association 
between MRP1 expression in human lung tumours and patient 
characteristics including age and gender.  Both studies did not find 
a significant association between the MRP1 score and the 
patient’s age, gender, (41,42) tumor size, presence of metastases, 
stage, or grade of differentiation, (41). However, they observed 
that MRP1 expression was found in tumours with lower TNM stage 
(stage 1) compared to higher TNM stage tumours possibly 
suggesting a protective role for MRP1.  
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The results of this study reveal significant correlation between 
delayed 99mTc-Sestamibi clearance and smoking status, increasing 
age and male gender.  Smoking was the single most important 
factor affecting clearance of inhaled sestamibi from the lungs. 
When we analysed the data for the effect of age, gender and 
locality of residence on inhaled sestamibi clearance including the 
smokers, there were no significant differences observed. However, 
upon exclusion of smokers, we observed increasing age 
(>30years) and male gender appear to delay inhaled sestamibi 
clearance (p<0.05).  There was however no significant correlation 
between locality of residence of participants and inhaled sestamibi 
clearance. This was analysed to assess the possible effect of 
atmospheric pollution in urban areas compared to those living in 
semi rural areas on inhaled sestamibi clearance. This however 
may not unexpected and may be difficult to evaluate given the 
nature of travel and lifestyle of individuals today. 
 
We also analysed the inhaled sestamibi clearance in smokers 
separately to see if the effect of age and gender still persisted. 
Interestingly we did not observe any significant impact of age or 
gender on inhaled sestamibi clearance between different groups of 
smokers. This suggested smoking was a single significantly strong 
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factor which affected clearance of inhaled sestamibi independent 
of other variables including age and gender. 
 
We ensured none of the participants were on a P-gp or MRP1 
modulating medication, including contraceptive medication, which 
could have biased the results.  
 
Whilst the results are significant, they cannot be attributed directly 
to the expression of MRP1 alone as we have 
immunohistochemistry confirmation in only a small number of 13 




The inhaled 99m Tc-sestamibi clearance technique is a repeatable 
and safe technique with estimated radiation exposure of <0.5 mSv. 
Bland Altman analysis of the test and retest results confirmed 
excellent agreement between the values in 9 patients with a mean 
error of 4.8 minutes and precision of 5.4 minutes. In one patient a 
>2SD deviation was observed. On further examination of records it 
was noted that the patient had stopped smoking between the first 
study when the inhaled 99m Tc-sestamibi clearance was 155 
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minutes and the repeat study 3 weeks later when the clearance 
time had significantly reduced to 125 minutes. This is an 
interesting observation as it raises the possibility that smoking 
cessation may have led to the down regulation of MRP1 resulting 
in the faster inhaled sestamibi clearance which would suggest a 
possible causal relation between MRP1 expression and inhaled 
sestamibi clearance.   
With the inclusion of the 10th patient the mean error was 7.1 
minutes with a precision of 9.3 minutes. There was also excellent 
inter-observer reproducibility observed p<0.05 supporting the 
robustness of the technique. (Table 2) 
Interestingly a faster clearance of the inhaled sestamibi values 
were noted generally in the repeat study compared to the first 
study resulting in a positive bias as seen on the Bland –Altman 
analysis. The variance however is well within a single standard 
deviation in most cases. It is possible that some of this positive 
bias may be due to patient related factors as all other imaging 
factors remained constant. The patient factors may be due to 
better inhalation technique due to familiarity, reduced 
apprehension and possibly stopping smoking for longer period the 




This study however is not without its limitations. The number of 
patients included in the study was small which makes 
interpretation of the results, although significant, at best a 
correlation rather than causal effect.   
We carried out the ventilation of the patients in an upright position 
rather than the standard supine position used in routine lung 
scintigraphy. This may have an impact on the tracer distribution, 
particularly the upper zones due to the effect of gravity. The 
upright acquisition however ensured good compliance with the 
technique in some patients who found it hard to lie down and 
ventilate.  However as the clearance was calculated over the 
whole lung, any effects of gravity did not affect the overall 
accuracy of the study. 
We also did not look at possible regional variation of the clearance 
values and did not analyse the clearance specifically related to 
tumour tissue, given the increased MRP1 expression noted in lung 
tumours compared to the normal lung tissue. However it has to be 
noted that the histopathology samples were non-uniform and the 
size of pathology was too small, 1-4 cm only. This poses difficulty 
to correlate spatially with ROIs in the dynamic images which are 
also subject to patient motion, respiratory motion and thereby 
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affecting the spatial correlation. In addition, due to the influence of 
noise in the dynamic images (short time frames), the use of small 
ROIs would have lead to errors related to this analysis.  
The best way of assessing the effect of different variables (Age, 
gender and smoking) on inhaled 99m Tc-sestamibi clearance would 
have been to use multi factorial regression analysis. However, 
given the very strong influence of a single factor, smoking and the 
relatively small numbers of the patients in the other individual 
groups, using regression analysis was not possible which was a 
drawback in our study to assess the effect of various factors on 
inhaled 99m Tc-sestamibi clearance. Future studies should be 
designed to assess this appropriately. 
 
14. Future direction: 
The results of the study raise many issues of which currently there 
is only limited understanding. Further larger studies correlating 
MRP1 expression with inhaled 99m Tc-sestamibi clearance, 
smoking status and specific MRP1 blockers would help shed light 
on this complex issue possibly opening an exciting alternative 
dimension in the study of drug transporters in the lung. This may 
have the potential to play a significant role in optimising inhaled 
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The study results indicate a significant correlation between the 
predominant transporter in lung (broncho-alveolar epithelium) 
MRP1 and inhaled 99mTc-Sestamibi clearance. Inhaled 99mTc- 
Sestamibi clearance is a safe and reproducible technique and 
smoking is a significant factor affecting the lung clearance strongly, 
with age and gender as well playing significant roles. There is 
however no definite effect of environmental status on the 
clearance rate observed. Further studies are required to determine 
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Positive P-glycoprotein staining in the control Gut epithelium tissue 







Positive Multidrug Resistance Protein 1 staining in the control Gut 
epithelium tissue (arrows pointing to intense brown staining within 









Colour scale used to grade the strength of immunostaining.  











































High power images of immunostaining of lung tissue in a patient clearly 
demonstrating negative P-gp staining with very little or no brown 






High power images of immunostaining of lung tissue in a patient clearly 






High power images of immunostaining of lung tissue in a patient clearly 
demonstrating Grade 1 brown staining for MRP1 (Arrows) 
 
The black arrows also indicate the location of the MRP1 within the 
ciliated broncho-alveolar epithelium. The red arrow indicated the airway 






High power images of immunostaining of lung tissue in a patient clearly 








High power images of immunostaining of lung tissue in a patient clearly 
demonstrating intense Grade 3 brown staining for MRP1 (Arrows)  













































































































































Bland-Altman analysis demonstrating excellent agreement between test 
and retest inhaled 99mTc-sestamibi clearance rates in 9 (4a) and 10 






























Smoking significantly prolonged clearance of inhaled sestamibi, 
Smokers, mean T1/2 = 142 +/- 29 minutes, compared to  



































Male participants demonstrated significant delayed clearance (T1/2 = 
128 +/-36 minutes) when compared to females mean T1/2 = 105 +/- 28 



















































There was however no significant difference noted between those living 
London (urban), mean T1/2 = 89 +/- 11 minutes and those in  




















































Increasing age resulted in delayed inhaled sestamibi clearance; >30yrs 
age, mean T1/2 = 134 +/- 31 minutes compared to 













Table 1 – Inhaled MIBI clearance for all patients 
 
Rt lung clearance Lt lung clearance Mean 
78 88 83 
102 101 101.5 
82 84 83 
99 103 101 
95 89 92 
78 89 83.5 
80 80 80 
85 88 86.5 
98 91 94.5 
86 88 87 
88 90 89 
107 102 104.5 
77 77 77 
67 66 66.5 
105 116 110.5 
75 76 75.5 
105 90 97.5 
145 101 123 
91 95 93 
147 138 142.5 
151 150 150.5 
203 199 201 
104 105 104.5 
138 141 139.5 
150 160 155 
158 151 154.5 
201 170 185.5 
123 115 119 
157 142 149.5 
129 140 134.5 
127 119 123 
113 107 110 
120 115 117.5 
173 178 175.5 
188 138 163 
 
Values of individual inhaled 99mTc-sestamibi clearance for each 
lung and the mean lung clearance for each patient. A Spearman 
Rho calculation confirmed an excellent correlation between the 
individual clearances between right and left lung with an R value 










































Values of lung clearances as calculated by 2 experienced nuclear 
medicine physicians. A Spearman Rho calculation confirmed an 
excellent correlation between the individual clearances with an R value 
0.97 and p<0.05. The lung clearance values measured as a mean value 
(both lungs) also demonstrate excellent correlation between the 2 
reviewers, R value 0.99 and p<0.001 
 
